alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Search

Search

314 results for "lecanemab".

Guides and answers on this site 29

Showing 11–20, page 2 of 3.

  1. Alzheimer's disparities by race, ethnicity & sexPage

    Research · alzhub.org/disparities

    … Phase 2 and Phase 3 lecanemab and elenbecestat trials in early Alzheimer's disease When Not specified; Phase 2/3 lecanemab and elenbecestat trials (pre-2023) Study found non-Hispanic Black participants were more likely than …

  2. Most-cited Alzheimer's studies: citations and RCRPage

    Research · alzhub.org/research/most-cited

    … retrieved 2026-09-24 3 Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine · randomised controlled trial 2023 618.61 4,522 iCite OpenAlex Semantic Scholar retrieved 2026-09-24 Summary This is the …

  3. How much difference do the new drugs actually make?Question

    Questions and answers · Treatment · alzhub.org/faq#how-well-do-they-work

    … trial (NCT03887455), lecanemab reduced decline on the CDR-SB rating scale by 0.45 points versus placebo — reported in the label as 27% less decline. Donanemab's trial (NCT04437511) showed a 2.92-point difference on the iADRS …

  4. What is ARIA, and how risky are these drugs?Question

    Questions and answers · Treatment · alzhub.org/faq#aria

    … report ARIA-E in 13% of lecanemab patients versus 2% on placebo, and in 24% of donanemab patients versus 2% on placebo. The labels state that ARIA “is usually asymptomatic, although serious and life-threatening events can occur” …

  5. The Alzheimer's life-course timelinePage

    Research · alzhub.org/life-course

    … doi:10.1038/s41591-024-03351-6 AHEAD 3-45 (lecanemab in preclinical AD) not yet reported Who: cognitively unimpaired adults 55-80 with intermediate or elevated brain amyloid; plasma Abeta42/40 used to screen before PET; …

  6. What the evidence says: vaccines, drugs, preventionPage

    Research · alzhub.org/correlation-studies

    … individual-level evidence only Lecanemab and cognitive/functional decline: 111 studies: Systematic review 9, Meta-analysis 3, RCT / clinical trial 14, Cohort 7, Case-control 1, Cross-sectional 2, Other / not reported 75; …

  7. Alzheimer's questions and answersPage

    Understand · alzhub.org/faq

    … Source: nia.nih.gov What are lecanemab (Leqembi) and donanemab (Kisunla), and who can take them? They are antibody infusions that clear beta-amyloid from the brain — the first treatments that change the underlying biology of …

  8. APOE4 by the numbers: one cohort and 766 studiesPage

    Research · alzhub.org/research/apoe4

    … participants · score 88/100 Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes The journal of prevention of Alzheimer's disease, 2026 · …

  9. Getting an Alzheimer's diagnosis and what comes afterPage

    Understand · alzhub.org/diagnosis

    … treatment People on lecanemab need brain MRIs to watch for swelling and small bleeds (ARIA): one before starting, and more before the 5th, 7th and 14th infusions. In the main lecanemab trial, ARIA showed on MRI in 12.6% of …

  10. Links the news suggests that nobody has testedPage

    Research · alzhub.org/research/opportunities

    … patients less likely to get lecanemab/donanemab (US patients). Surfaced by Who gets Alzheimer's drugs? Race, vulnerability and health status shape access (Medical Xpress, 2026-10-15) and 1 other news article. What the library …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

28381 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-06. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.